Back to Search Start Over

Subterminal hydroxyeicosatetraenoic acids: Crucial lipid mediators in normal physiology and disease states.

Authors :
Shoieb, Sherif M.
El-Sherbeni, Ahmed A.
El-Kadi, Ayman O.S.
Source :
Chemico-Biological Interactions. Feb2019, Vol. 299, p140-150. 11p.
Publication Year :
2019

Abstract

Abstract Cytochrome P450 (P450) enzymes are superfamily of monooxygenases that hold the utmost diversity of substrate structures and catalytic reaction forms amongst all other enzymes. P450 enzymes metabolize arachidonic acid (AA) to a wide array of biologically active lipid mediators. P450-mediated AA metabolites have a significant role in normal physiological and pathophysiological conditions, hence they could be promising therapeutic targets in different disease states. P450 monooxygenases mediate the (ω-n)-hydroxylation reactions, which involve the introduction of a hydroxyl group to the carbon skeleton of AA, forming subterminal hydroxyeicosatetraenoic acids (HETEs). In the current review, we specified different P450 isozymes implicated in the formation of subterminal HETEs in varied tissues. In addition, we focused on the role of subterminal HETEs namely 19-HETE, 16-HETE, 17-HETE and 18-HETE in different organs, importantly the kidneys, heart, liver and brain. Furthermore, we highlighted their role in hypertension, acute coronary syndrome, diabetic retinopathy, non-alcoholic fatty liver disease, ischemic stroke as well as inflammatory diseases. Since each member of subterminal HETEs exist as R and S enantiomer, we addressed the issue of stereoselectivity related to the formation and differential effects of these enantiomers. In conclusion, elucidation of different roles of subterminal HETEs in normal and disease states leads to identification of novel therapeutic targets and development of new therapeutic modalities in different disease states. Highlights • Subterminal HETEs are biologically active arachidonic acid metabolites. • 16-, 17-, 18- and 19-HETE play a role in health and disease states. • Subterminal HETEs modulators are potential new therapy for cardiovascular diseases. • Sexual dimorphism of P450 enzymes affects subterminal HETEs biosynthesis and levels. • FDA-approved drugs could be repurposed to modulate the levels of subterminal HETEs. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00092797
Volume :
299
Database :
Academic Search Index
Journal :
Chemico-Biological Interactions
Publication Type :
Academic Journal
Accession number :
134184255
Full Text :
https://doi.org/10.1016/j.cbi.2018.12.004